ABSI

Absci Corporation operates as a generative AI drug creation company that combines artificial intelligence with synthetic biology to discover and develop biologic therapeutics. Headquartered in Vancouver, Washington, the company maintains laboratories and offices across the United States and Europe. Absci's proprietary platform integrates AI-enabled drug design with its high-throughput wet lab capabilities, allowing pharmaceutical partners to design and validate antibodies and other protein-based drugs with improved properties. The company generates revenue through partnerships with pharmaceutical and biotechnology companies, providing drug discovery services and entering into licensing agreements for therapeutic candidates. Notable collaborations include partnerships with major pharmaceutical companies such as Merck and AstraZeneca. Absci's technology enables the creation of de novo antibodies and the optimization of existing therapeutic proteins, addressing challenges in traditional drug discovery such as developability, immunogenicity, and manufacturing efficiency. The company operates its proprietary E. coli-based protein expression platform, which facilitates rapid screening of billions of drug candidates. Since its public debut in 2021 through a SPAC merger, Absci has focused on advancing its internal pipeline while expanding its partnership network. The company employs several hundred staff members across its research, computational biology, and business development functions, positioning itself within the emerging artificial intelligence-driven drug discovery sector.